3.29.17 New Treatment Update: In late March, the FDA approved niraparib, a PARP inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. This is exciting news because it is the first PARP inhibitor to be approved by the FDA that does not require a woman to have a BRCA mutation.
Niraparib has been approved for women who are in complete or partial response to platinum-based chemotherapy. It has not been approved for women who are platinum-resistant.
“This is promising news because it gives more options for women who are living with recurrent ovarian cancer, especially those who are not BRCA positive,” said Kathleen Gavin, MOCA’s executive director. “We recommend that women who have completed and responded to platinum-based chemotherapy talk with their doctor to see if this new drug is an option for them.”
Tesaro, the company manufacturing the drug, expects to launch niraparib in the U.S. in late April. Tesaro will be marketing the drug under the brandname Zejula. Niraparib is a once-daily, oral drug. Read the press release on niraparib from Tesaro here.